Axumin PET scan
PreclinicalSmall molecule
Axumin PET scan is one of 56 small molecule programs targeting Germ Cell Tumor. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
55
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
81 competitors in Germ Cell Tumor
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 3
Vepesid
AAvyxa
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Ifex
BBaxter Healthcare Corporation
Phase 3
Blenoxane
Bristol-Myers SquibbPhase 3
Eloxatin
TevaPhase 3
Blenoxane
SSequus Pharmaceuticals
Phase 3
Velban
Eli LillyPhase 3
Etopophos
GGerman Society for Pediatric Oncology and Hematology GPOH gGmbH
Phase 3
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Axumin PET scan. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details